论文部分内容阅读
对于抗癌药物的开发者来说,p53信号通路是一个首当其中的靶向位点.但是目前治疗策略却不容乐观,因为许多p53调控蛋白通过蛋白-蛋白相互作用来调节p53的活性,这使得靶向治疗很难实现。
The p53 signaling pathway is the first target site for anticancer drug developers, but the current strategy is not optimistic because many p53 regulatory proteins regulate p53 activity through protein-protein interactions, which Making targeted therapy is difficult to achieve.